BTIG Initiates Coverage On Genmab with Buy Rating, Announces Price Target of $44
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Kaveri Pohlman has initiated coverage on Genmab (NASDAQ:GMAB) with a Buy rating and a price target of $44.
August 24, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab has received a Buy rating from BTIG with a price target of $44.
The Buy rating and price target set by BTIG indicates a positive outlook for Genmab. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100